Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Optimization of the Healing Process of the Uterine Scar Tissue After Re-cesarean Section

N/ACompletedNCT02703519
Martin-Luther-Universität Halle-Wittenberg116 enrolled

Overview

This prospective, controlled, clinical, intervention study measures the number of uterine Cesarean section scars and median myometrial thickness of women who underwent two Cesarean sections six to nine months after their last Cesarean section using transvaginal ultrasound. It is the purpose of the study to assess if a resection of the uterine scar from a previous Cesarean section during a second Cesarean section could lead to a decrease in risk for subsequent pregnancies.

The average number of Cesarean sections in Germany has doubled from 1991 to 2011, making up 32,1% of all deliveries in 2011. Several studies describe instances in which pregnancies following a previous Cesarean section were accompanied by complications such as life-threatening bleeding, placenta previa, placenta accreta, increta or percreta and dehiscence or uterine rupture. The risk of those complications increases further with the uterine scar tissue of a second Cesarean section. Today it is already common practice to resect uterine scars if the scar of a previous Cesarean section becomes symptomatic, or when a non-symptomatic uterine rupture or serious dehiscence are discovered during a Cesarean delivery. In this study all participants of the interventional group are examined via intraoperative ultrasound to identify the first uterine Cesarean section scar and resect it completely. Six to nine months after the resection participants will return for a one time follow-up. At this time, the investigators will measure the number of uterine scars and median myometrial thickness using transvaginal ultrasound. The results will be compared with those of two control groups, consisting of women who underwent either one or two Cesarean sections without the intervention. The aim of the present study is to asses if the number of uterine scars and median myometrial thickness can be improved by the resection of the first uterine scar during a subsequent Cesarean section. This will allow the investigators to draw conclusions regarding the benefit of routine resections of uterine Cesarean section scars, and whether this practice could lead to a decreased risk for women undergoing two or more Cesarean sections.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

116

Conditions

Scar; Previous Cesarean SectionComplications; Cesarean Section, Wound, Dehiscence

Interventions

resection of uterine scar tissuePROCEDURE

resection of uterine scar tissue of a previous cesarean section during a second cesarean section

Eligibility

Sex: FEMALEMin age: 18 Years
Medical Language ↔ Plain English
Inclusion Criteria: * 18 years or older * primary or secondary indication for cesarean section 6 to 9 months prior to the examination date Exclusion Criteria: * \<18 years old * current pregnancy * congenital deformity of the uterus * former surgery of the uterine myometrium

Locations (2)

Maternity Clinic/Perinatal Treatment Center, Halle University Hospital, Martin-Luther-Universität Halle-Wittenberg

Halle, Saxony-Anhalt, Germany

Maternity Clinic, Magdeburg University Hospital

Magdeburg, Saxony-Anhalt, Germany

Outcomes

Primary Outcomes

number of uterine Cesarean section scars using transvaginal ultrasound

Time frame: 6-9 months

Secondary Outcomes

median myometrial thickness of lower uterine segment using transvaginal ultrasound

Time frame: 6-9months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.